Fluorocyclopentenylcytosine

DB16168InvestigationalSmall molecule

Fluorocyclopentenylcytosine is under investigation in clinical trial NCT03189914 (RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer).

Formula / weight: C₁₀H₁₂FN₃O₄ · 257.221 g/mol (avg)
Also known as: 4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl) cyclopent-2-en-1-yl] pyrimidin-2-one · Roducitabine
Code names: RX-3117 · TV-1360

Resolves to

Compound

UNII0Z4A82I0JOCAS865838-26-2ChEMBLCHEMBL2064455ChEBI147412

Structure

InChIKeyQLLGKCJUPWYJON-HLTSFMKQSA-NSMILESNC1=NC(=O)N(C=C1)[C@H]1[C@H](O)[C@H](O)C(CO)=C1F

Targets

P26358DNMT1

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Fluorocyclopentenylcytosine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account